Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and maintains the target price at $1,195.
According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations marginally in terms of revenue and more significantly regarding earnings per share. However, the performance of the Eylea franchise was a dominant concern. The impending launch of a biosimilar version of Eylea by a competitor has raised questions about the future of the franchise. This includes the pace at which the standard dose market may decline, which may be faster than current market estimates, and the potential negative impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an overextension. This sentiment is in response to reactions concerning the Pavblu news, the less-than-anticipated Q4 Eylea HD outlook, and the absence of forward-looking growth projections for Eylea.
The stock's decline post-Q3 earnings was somewhat unexpected. This was given the understanding that near- and long-term consensus estimates for the ophthalmology franchise might have been overly optimistic. Nonetheless, it appears that the fundamental fair value of Regeneron is currently well above where the shares are trading.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Christopher Raymond維持$再生元製藥公司 (REGN.US)$買入評級，維持目標價1,195美元。
根據TipRanks數據顯示，該分析師近一年總勝率為53.1%，總平均回報率為4.4%。
此外，綜合報道，$再生元製藥公司 (REGN.US)$近期主要分析師觀點如下：
Regeneron的第三季度業績在收入方面略有超出預期，更重要的是每股收益。但是，Eylea系列的表現是一個主要問題。競爭對手即將推出的生物仿製藥版本的Eylea引發了人們對該系列未來的質疑。這包括標準劑量市場可能下降的速度（可能比目前的市場估計更快），以及對高劑量變體的潛在負面影響。
Regeneron最近股價的下跌被視爲過度擴張。這種情緒是對Pavblu新聞、不如預期的第四季度Eylea HD前景以及Eylea缺乏前瞻性增長預測的反應的回應。
該股在第三季度後收益的下降有些出乎意料。這是因爲我們認識到，眼科專營權的短期和長期共識估計可能過於樂觀。儘管如此，Regeneron目前的基本公允價值似乎遠高於股票的交易價格。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
